Eloxx Pharmaceuticals, Inc.
ELOX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $24 | $46 | $15 | $26 |
| G&A Expenses | $11 | $20 | $15 | $24 |
| SG&A Expenses | $11 | $20 | $15 | $24 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $34 | $66 | $29 | $51 |
| Operating Income | -$34 | -$66 | -$33 | -$51 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2 | -$1 | -$1 | -$0 |
| Pre-Tax Income | -$36 | -$67 | -$35 | -$51 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$36 | -$67 | -$35 | -$51 |
| % Margin | – | – | – | – |
| EPS | -16.65 | -38.15 | -34.47 | -53.46 |
| % Growth | 56.4% | -10.7% | 35.5% | – |
| EPS Diluted | -16.65 | -38.15 | -34.47 | -53.46 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $2 | $1 | $1 | $2 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$32 | -$65 | -$33 | -$49 |
| % Margin | – | – | – | – |